Invention Grant
- Patent Title: Combination therapies comprising apremilast and Tyk2 inhibitors
-
Application No.: US16398569Application Date: 2019-04-30
-
Publication No.: US11357775B2Publication Date: 2022-06-14
- Inventor: Peter Henry Schafer , Robert Plenge , Mary Adams , Lisa Beebe , Gilles Buchwalter , Tiffany Carr , Te-chen Tzeng
- Applicant: Celgene Corporation
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: McCarter & English, LLP
- Agent Basil S. Krikelis; Michael J. DeGrazia
- Main IPC: A61K31/501
- IPC: A61K31/501 ; A61P17/06 ; A61K9/00
Abstract:
Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
Public/Granted literature
- US20200345731A1 COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS Public/Granted day:2020-11-05
Information query
IPC分类:
